Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 24, 2018

Primary Completion Date

July 31, 2025

Study Completion Date

November 30, 2025

Conditions
Viral Infection
Interventions
BIOLOGICAL

CMV/AdV /EBV/BKV specific T cells

Each cohort of 2 patients will be treated and observed for 45 days for toxicity, dose escalation, and GvHD. The algorithm of sequentially adaptive EffTox trade-off-based design of Thall et al will be used to determine the dose for each cohort. If 1x107CTL/m2 results in unacceptable toxicity or efficacy, the study will be closed to accrual.

Trial Locations (2)

20010

RECRUITING

Children's National Health System, Washington D.C.

77030

RECRUITING

M.D. Anderson Cancer Center (MDACC), Houston

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

Catherine Bollard

OTHER